Combination treatments with hydroxychloroquine and azithromycin are compatible with the therapeutic induction of anticancer immune responses

Amid controversial reports that COVID-19 can be treated with a combination of the antimalarial drug hydroxychloroquine (HCQ) and the antibiotic azithromycin (AZI), a clinical trial (ONCOCOVID, NCT04341207) was launched at Gustave Roussy Cancer Campus to investigate the utility of this combination th...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Peng, Zhao, Liwei, Ferrere, Gladys, Alves-Costa-Silva, Carolina, Ly, Pierre, Wu, Qi, Tian, Ai-Ling, Derosa, Lisa, Zitvogel, Laurence, Kepp, Oliver, Kroemer, Guido
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2020
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7458592/
https://www.ncbi.nlm.nih.gov/pubmed/32923151
http://dx.doi.org/10.1080/2162402X.2020.1789284

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7458592/
https://www.ncbi.nlm.nih.gov/pubmed/32923151
http://dx.doi.org/10.1080/2162402X.2020.1789284

Ejemplares similares